Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

Stopped early · Phase 4

Conditions studied: Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity

In brief

The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.

Key facts

Study ID

NCT01017263

Run by

Duke University

People needed

14

Starts

2009-12-01

Expected to finish

2012-08-01

Last updated by the study team

2014-02-20

Who can join

Age: 8 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• male or female, ages between 8 and 17
• Body Mass Index > 30
• fasting blood sugar between 90-100 mg/dl
• 2 hour post prandial >140 <180 mg/dl
• meets criteria for a diagnosis of ADHD, any subtype

You may not qualify if…

• known cardiovascular disease or diabetes
• structural cardiac abnormalities, abnormal ECGs, family history of sudden death
• positive urine drug screen
• fasting blood sugar level > 126 mg/dl
• HbA1c > 6.5 %
• Weight > 300 lbs

Where it is running

• Duke Child and Family Study Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.